Document Classification

Section Type: METHODS

Text: Between November 1999 and November 2004, 211 patients with relapsed or refractory GCT were randomly assigned to treatment with either one cycle of cisplatin 100 mg/m (2), etoposide 375 mg/m (2), and ifosfamide 6 g/m (2) (VIP) plus three cycles of high-dose carboplatin 1, 500 mg/m (2) and etoposide 1, 500 mg/m (2) (CE, arm A) or three cycles of VIP plus one cycle of high-dose carboplatin 2, 200 mg/m (2), etoposide 1, 800 mg/m (2), and cyclophosphamide 6, 400 mg/m (2) (CEC, arm B) followed by autologous stem-cell reinfusion.